{
  "id": "61f5924e882a024a1000000e",
  "type": "list",
  "question": "Belzutifan has shown effectiveness for which diseases?",
  "ideal_answer": "Belzutifan is the small-molecule HIF 2 alpha inhibitor that has demonstrated significant efficacy in the von Hippel-Lindau disease related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors while demonstrating an acceptable safety profile",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34482771",
    "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
    "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
    "http://www.ncbi.nlm.nih.gov/pubmed/33931436",
    "http://www.ncbi.nlm.nih.gov/pubmed/33945366",
    "http://www.ncbi.nlm.nih.gov/pubmed/34590859",
    "http://www.ncbi.nlm.nih.gov/pubmed/34479868"
  ],
  "snippets": [
    {
      "text": "AIM AND RESULTS: This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2\u03b1 inhibitor belzutifan)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Belzutifan (Welireg\u2122) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2\u03b1 being developed by Peloton Therapeutics for the treatment of solid tumours, including renal cell carcinoma (RCC) with clear cell histology (ccRCC) and von Hippel-Lindau (VHL) disease-associated RCC. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A detailed mechanistic understanding of a benzylic photobromination en route to belzutifan (MK-6482, a small molecule for the treatment of renal cell carcinoma associated with von Hippel-Lindau syndrome) has been achieved using in situ LED-NMR spectroscopy in conjunction with kinetic analysis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590859",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The small-molecule HIF 2 alpha inhibitor MK-6482 (belzutifan) has demonstrated significant efficacy in VHL disease related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors while demonstrating an acceptable safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33945366",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The HIF2\u03b1 Inhibitor Belzutifan Shows Signs of Efficacy in Kidney Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33931436",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "en-label, single-group trial, we investigated the efficacy and safety of the HIF-2\u03b1 inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was o",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ifestations. The small-molecule HIF 2 alpha inhibitor MK-6482 (belzutifan) has demonstrated significant efficacy in VHL disease related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors while demonstrating an acceptable safet",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33945366",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "21, belzutifan received its first approval in the USA for the treatment of patients with VHL disease who require therapy for associated RCC, central nervous system (CNS) haemangioblastomas or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery. Clinical studies",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Belzutifan (Welireg\u2122) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2\u03b1 being developed by Peloton Therapeutics for the treatment of solid tumours, including renal cell carcinoma (RCC) with clear cell histology (ccRCC) and von Hippel-Lindau (VHL) disease-associated RCC. In August",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " belzutifan (as monotherapy or combination therapy) in other indications, including ccRCC, pNET and phaeochromocytoma/paraganglioma, are also underway in various countries. This article summarize",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nifestations. The small-molecule HIF 2 alpha inhibitor MK-6482 (belzutifan) has demonstrated significant efficacy in VHL disease related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors while demonstrating an acceptable safety profile.AREAS COVERED: This paper reviews the development of the HIF-2 alpha inhibitor, MK-6482, and discusses preliminary results of ongoing phase I/II studies in renal cell car",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33945366",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Belzutifan (Welireg\u2122) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2\u03b1 being developed by Peloton Therapeutics for the treatment of solid tumours, including renal cell carcinoma (RCC) with clear cell histology (ccRCC) and von Hippel-Lindau (VHL) disease-associated RCC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical studies of belzutifan (as monotherapy or combination therapy) in other indications, including ccRCC, pNET and phaeochromocytoma/paraganglioma, are also underway in various countries.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl).CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carci",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34818478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In August 2021, belzutifan received its first approval in the USA for the treatment of patients with VHL disease who require therapy for associated RCC, central nervous system (CNS) haemangioblastomas or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34613603",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "renal cell carcinomas, hemangioblastomas, pancreatic neuroendocrine tumors"
}